Study determines drowning victims' corneas safe for transplantation

News
Article

The study, based out of India, successfully transplanted 32 of 34 corneas harvested from drowning victims.

Hand holding paper cutout of eye against blue blackdrop Image Credit: AdobeStock/Orawan

Image Credit: AdobeStock/Orawan

Donor corneas obtained from individuals who drowned are safe for transplantation,1 according to researchers from the Cornea and Anterior Segment Service, L V Prasad Eye Institute, Bhubaneswar, Odisha, India.

Kshyanaprava Priyadarshini, MS, first author of the study, described the retrospective investigation that led to this result. The aim of this study, she recounted, was to analyze the tissue quality and outcomes of corneal transplantations from donor corneal tissues harvested from drowning victims from March 2018 to September 2022. The details of the quality of the corneal tissue and the outcomes after the corneal transplantations were collected from the eye bank and outpatient records.

Over the course of the study, 34 donor corneas were obtained from drowning victims who were a mean age of 37.1 ± 20.3 years) The mean time from when the tissue was obtained to its preservation was 4.9 ± 2.6 hours.

The mean endothelial cell density of the donor corneas was 3,025 ± 271 cells/mm2. Of the 34 corneas, 20 (58.8%) were transplanted at the L V Prasad Eye Institute, 2 were stored in glycerol for future use, and 12 were transported to other transplantation centers. Overall, 94.1% or 32 corneas were transplanted.

Of the 20 corneas used at the L V Prasad Eye Institute, 17 were used for optical grafts and 3 for therapeutic indications, according to Ms. Priyadarshini. Of the 17 optical grafts, 10 were used for optical penetrating keratoplasty, 6 for endothelial keratoplasty, and 1 for anterior lamellar keratoplasty. The most common indication for keratoplasty was regrafting because of a previously failed graft (25%), she reported. No infections developed in any of the transplanted eyes during the immediate postoperative period. Eight eyes had clear grafts after 3 months.

Of the 12 tissues transferred to other keratoplasty centers, 10 were used for optical grafts and 2 for therapeutic/tectonic grafts.

The researchers concluded, “Donor corneas retrieved from drowning victims may be considered safe for transplantation. The postoperative outcomes of the tissues obtained from these donors were satisfactory. Hence, these donor corneas can be optimally used in routine transplantation procedures.”

Reference
PriyadarshiniK,Das S, Sahu SK, et al. Safety and efficacy profile of corneas harvested from donors of drowning victims. Cornea. 2024;43:141-145; doi: 10.1097/ICO.0000000000003321

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dana Shannon, OD, FAAO, detailed a lecture she gave at the NOA Midwestern Symposium earlier this month.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, gave 2 presentations alongside other ODs and MDs at CRU 2025.
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
© 2025 MJH Life Sciences

All rights reserved.